| Bioactivity | c-Met-IN-23 (Compound 12g) is a c-Met inhibitor (IC50 = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent[1]. |
| Invitro | c-Met-IN-23 (72 h) inhibits HGF-induced cell proliferation, with IC50s of 12.4, 3.06, 19.30, 16.85 µM for HT29, HepG2, MCF7, MDA-MB-231 cells respectively[1].c-Met-IN-23 (0.3-150 µM, 30 min) blocks P-gp and MRP1/2 pumps in both HepG2 and BxPC3 cells[1].c-Met-IN-23 (3 µM, 24 h) increases the expression of P-gp in HepG2 and BxPC3 cells, as well as MRP1 and MRP2 in BxPC3 cells, and inhibits the P-gp-mediated efflux in HepG2 cell[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> c-Met-IN-23 相关抗体: |
| Formula | C16H13N7O |
| Molar Mass | 319.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Khatir ZZ, et al. 4-{3-[(Pyridin-4-ylmethyl)amino]-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl}phenol: An improved anticancer agent in hepatocellular carcinoma and a selective MDR1/MRP modulator. Arch Pharm (Weinheim). 2024 Mar 5:e2300704. |